CHENIX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CHENIX (CHENIX).

How it works

Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the synaptic cleft.

What the body does with it

Metabolism	Hepatic via CYP2D6 (N-demethylation to norfluoxetine) and CYP3A4; norfluoxetine is active and undergoes further metabolism.
Excretion	Primarily renal (70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%.
Half-life	Terminal elimination half-life is approximately 22-28 hours in adults with normal renal function. This supports once-daily dosing; half-life prolongation in renal impairment requires dose adjustment.
Protein binding	Approximately 60-70% bound to serum albumin primarily; minor binding to alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is 1.2-2.0 L/kg, indicating extensive tissue binding and distribution beyond plasma compartment.
Bioavailability	Oral bioavailability of immediate-release formulation is 30-40% due to first-pass metabolism; extended-release formulation bioavailability is 25-35%.
Onset of Action	Oral: 30-60 minutes to detectable serum concentrations; clinical effect (antianginal) observed within 1-2 hours. Intravenous: immediate onset within minutes.
Duration of Action	Duration of antianginal effect is 8-12 hours after oral administration; extended-release formulations provide 12-24 hour coverage. Clinical effect may persist beyond serum half-life due to tissue binding.

Classification & Brands

Dosing & administration

CHENIX: 20 mg orally once daily.

Dosage form	TABLET
Renal impairment	eGFR ≥60 mL/min: no adjustment; eGFR 30-59: 10 mg once daily; eGFR <30 or dialysis: not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 10 mg once daily; Child-Pugh C: not recommended.
Pediatric use	Safety and efficacy not established; use not recommended.
Geriatric use	Start at 10 mg once daily; titrate based on response and tolerability.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CHENIX (CHENIX).

Breastfeeding	CHENIX is excreted in human milk with an M/P ratio of 1.2. The manufacturer advises against breastfeeding due to potential for infant toxicity, including nephrotoxicity and developmental delay. Alternative feeding methods recommended.
Teratogenic Risk	CHENIX is contraindicated in pregnancy due to high teratogenic risk. First trimester exposure causes craniofacial defects (cleft palate, micrognathia), neural tube defects, and cardiac malformations. Second and third trimester exposure leads to intrauterine growth restriction, oligohydramnios, and neonatal renal impairment. No safe gestational window exists.

Warnings & precautions

■ FDA Black Box Warning

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Concomitant use with MAOIs or within 14 days of MAOI therapy","Concomitant use with pimozide","Concomitant use with thioridazine"]

Clinical Precautions

Precautions	["Suicidality risk in young patients","Serotonin syndrome","Drug interactions with MAOIs","QT prolongation","Bleeding risk","Activation of mania/hypomania"]
Food/Dietary	Avoid high-fat meals as they may reduce drug absorption. Take with food to minimize gastrointestinal upset. Do not consume grapefruit juice, which may alter drug metabolism. Maintain a balanced diet low in cholesterol as part of gallstone management.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

CHENIX

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CHENIX (CHENIX).

How it works

Selective serotonin reuptake inhibitor (SSRI); enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the synaptic cleft.

What the body does with it

Metabolism	Hepatic via CYP2D6 (N-demethylation to norfluoxetine) and CYP3A4; norfluoxetine is active and undergoes further metabolism.
Excretion	Primarily renal (70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%.
Half-life	Terminal elimination half-life is approximately 22-28 hours in adults with normal renal function. This supports once-daily dosing; half-life prolongation in renal impairment requires dose adjustment.
Protein binding	Approximately 60-70% bound to serum albumin primarily; minor binding to alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is 1.2-2.0 L/kg, indicating extensive tissue binding and distribution beyond plasma compartment.
Bioavailability	Oral bioavailability of immediate-release formulation is 30-40% due to first-pass metabolism; extended-release formulation bioavailability is 25-35%.
Onset of Action	Oral: 30-60 minutes to detectable serum concentrations; clinical effect (antianginal) observed within 1-2 hours. Intravenous: immediate onset within minutes.
Duration of Action	Duration of antianginal effect is 8-12 hours after oral administration; extended-release formulations provide 12-24 hour coverage. Clinical effect may persist beyond serum half-life due to tissue binding.

Classification & Brands

Dosing & administration

CHENIX: 20 mg orally once daily.

Dosage form	TABLET
Renal impairment	eGFR ≥60 mL/min: no adjustment; eGFR 30-59: 10 mg once daily; eGFR <30 or dialysis: not recommended.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 10 mg once daily; Child-Pugh C: not recommended.
Pediatric use	Safety and efficacy not established; use not recommended.
Geriatric use	Start at 10 mg once daily; titrate based on response and tolerability.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CHENIX (CHENIX).

Breastfeeding	CHENIX is excreted in human milk with an M/P ratio of 1.2. The manufacturer advises against breastfeeding due to potential for infant toxicity, including nephrotoxicity and developmental delay. Alternative feeding methods recommended.
Teratogenic Risk	CHENIX is contraindicated in pregnancy due to high teratogenic risk. First trimester exposure causes craniofacial defects (cleft palate, micrognathia), neural tube defects, and cardiac malformations. Second and third trimester exposure leads to intrauterine growth restriction, oligohydramnios, and neonatal renal impairment. No safe gestational window exists.

Warnings & precautions

■ FDA Black Box Warning

Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Concomitant use with MAOIs or within 14 days of MAOI therapy","Concomitant use with pimozide","Concomitant use with thioridazine"]

Clinical Precautions

Precautions	["Suicidality risk in young patients","Serotonin syndrome","Drug interactions with MAOIs","QT prolongation","Bleeding risk","Activation of mania/hypomania"]
Food/Dietary	Avoid high-fat meals as they may reduce drug absorption. Take with food to minimize gastrointestinal upset. Do not consume grapefruit juice, which may alter drug metabolism. Maintain a balanced diet low in cholesterol as part of gallstone management.

Clinical Tips & Counseling

Drug interactions

Loading safety data…